Several members of the Gram-negative environmental bacterial genus, Achromobacter, are 24 associated with serious infections in immunocompromised individuals, of which 25
purified isolate to obtain an accurate speciation result, which limits the utility of this platform 83 as it cannot be used directly on polymicrobial clinical specimens such as sputum, resulting in 84 longer turn-around times, potentially incorrect antimicrobial treatment, and higher costs (19, 85 20) . In addition, mass spectrometry-based equipment has a large upfront cost and footprint, 86 rendering this method out-of-reach for smaller, less-resourced laboratories. To address this 87 shortcoming, an automated multiplex PCR has recently been developed to detect four non-88 fermentative Gram negative bacterial species, including A. xylosoxidans, directly from 89 respiratory samples using the BD MAX™ System (18) . This multiplex assay detected A. 90 xylosoxidans with 97% specificity, but only 78% sensitivity (18), indicating suboptimal 91 diagnosis of this organism using this method. Further, the BD MAX™ multiplex assay was not 92 designed to identify other Achromobacter spp., meaning that ~50% of CF infections caused 93 by Achromobacter spp. cannot be diagnosed with this method. Other genotyping methods 94 such as amplified ribosomal DNA restriction analysis (ARDRA) (21), multilocus sequence 95 typing (22), nrdA gene sequencing (12), and whole-genome sequencing (WGS) provide robust 96 identification and speciation methods for Achromobacter spp., but are laborious and cannot 97 be performed in a rapid or cost-effective manner. 98
Here, we used a large-scale comparative genomic approach to identify genetic loci specific to 99 all Achromobacter species, and to A. xylosoxidans only. We subsequently designed a highly 100 specific and accurate Achromobacter spp. and A. xylosoxidans (Ac-Ax) duplex PCR assay for 101 the simultaneous detection of these organisms. Phylogenomic analysis of 158 Achromobacter 102 genomes, including 65 A. xylosoxidans genomes, was used to robustly identify species 103 boundaries and to reassign several incorrect taxon assignments. Candidate genetic regions 104 specific for all Achromobacter spp. and for A. xylosoxidans were then assessed for assay 105 design suitability, followed by Ac-Ax duplex assay development and validation on 153 isolates 106 comprising 116 Achromobacter spp., 48 A. xylosoxidans, and 34 non-Achromobacter spp. 107
Finally, the Ac-Ax duplex assay was tested on 38 CF sputa DNA obtained from 21 adults, four 108 of whom were positive for Achromobacter spp. according to 16S rRNA gene metataxonomic 109 sequencing, to determine assay specificity and sensitivity in polymicrobial specimens. 110 genomes (Table S1) using default parameters embedded in the SPANDx v3.2.1 comparative 138 genomics software. The -m flag of SPANDx was employed to identify biallelic, orthologous, 139 core-genome single-nucleotide polymorphisms (SNPs) among all genomes (28). Both 140 simulated and real Illumina reads were mapped against the A. xylosoxidans NCTC 10807 141 reference genome (GenBank reference NZ_LN831029.1). Phylogenomic reconstruction was 142 carried out on the 174,240 biallelic orthologous SNPs identified among all 158 Achromobacter 143 spp. strains using the heuristic maximum parsimony function of PAUP* v4.0a.165 (29) . The 144 resultant phylogenomic tree (Figure 1 ) was bootstrapped for 1,000 replicates and midpoint-145 rooted using FigTree v1.4.0 prior to visualisation. The BEDcov output generated by BEDTools 146 (30), which is wrapped in the SPANDx pipeline, was used to identify conserved candidate loci 147 for subsequent real-time PCR assay design. 148
Identification of genetic loci specific for A. xylosoxidans, and for all Achromobacter 149 spp. Using the BEDcov output generated by default by the SPANDx pipeline, a total of ~9kb 150 of DNA across four discrete loci was identified as highly conserved across all A. xylosoxidans 151 strains (n=65), but absent or highly divergent in other Achromobacter spp. (n=94) ( Table 1) . 152
The sequences for these loci were examined by Microbial Nucleotide BLAST 153 (http://blast.ncbi.nlm.nih.gov; performed November 2019) to identify candidate regions for 154 real-time PCR assay design. Using this approach, the AT699_RS16685 locus, which encodes 155 a hypothetical protein in A. xylosoxidans, was selected for assay design. The process for 156 designing the Achromobacter spp. assay was different due to the need to cater for more 157 genetic diversity across all Achromobacter strains. The highly conserved rpoB gene, which 158 encodes DNA-directed RNA polymerase β-subunit protein, was targeted for assay design. 159
Ac-Ax duplex real-time PCR assay design. DNA sequences from these candidate loci for 160 all 158 strains (for the Ac assay) and for the 65 A. xylosoxidans strains (for the Ax assay) were 161 extensively assessed for specificity using several in silico methods as detailed elsewhere (31). 162
The following primers and Black Hole Quencher (BHQ) probes were designed for specific 163
Achromobacter spp. and A. xylosoxidans detection, respectively (5' to 3'): Ac_F 164 (CACrTAGCTCACGAACTCCAAGC), Ac_R (CAGCTTCAATCCTACCTAACTTTCCT), and 165
Ac_probe (HEX-CGTAGCCGACGGTTTGCAGG-BHQ1), which generates a 144bp amplicon; 166 and Ax_F (AGCGTCACGGAATGCAGC), Ax_R (AAGGGCGTTTCAACGAGAGC) and 167
Ax_probe (FAM-AGGTCATAGGCGTAGACCAGC-BHQ1), which generates a 127bp 168 amplicon. Amplicon specificity was verified using Microbial Nucleotide BLAST. 169 ii) API 20 NE phenotypic testing (n=85); iii) ARDRA (n=13), and iv) WGS (n=5) ( Table S2) . 189
Real
Among the Australian strains, two were previously identified as A. ruhlandii (QLDACH007 and 190 QLDACH010) and two as A. xylosoxidans (QLDACH001 and AUS488) according to WGS (35, 191 36) , one (QLDACH016) was a novel Achromobacter sp. according to WGS (36), and 110 were 192 allocated as Achromobacter sp. according to API 20 NE, ARDRA, or VITEK ® MS. Strains were 193 grown on chocolate agar for 24h at 37 °C prior to chelex DNA extraction, as described 194 elsewhere (31). by ARDRA or API 20 NE testing) that were negative for the Ac-Ax duplex assay to assign 215 species designations. The ~1.3kb 16S rDNA amplicons were generated using primers 785F 216 CT value (i.e. ΔCT). 230
Results 231
Comparative genomic analysis of Achromobacter spp. Phylogenomic reconstruction of 232 the 158 Achromobacter genomes confirmed that all taxa were Achromobacter spp. However, 233 a considerable number of taxonomic errors (n=36; ~23%) were identified in the dataset ( Figure  234 1, black boxes). Taxonomic reassignment was therefore carried out to ensure correct 235 delineation of the A. xylosoxidans clade from all other Achromobacter spp. for PCR assay 236 design (Table S1 ). In total, 29 Achromobacter clades were identified among the 158 genomes, 237 of which only 14 corresponded to a previously assigned species. The remaining 15 clades 238 lack a type species genome for comparison and may correspond to several novel species 239 of the 144bp Ac amplicon identified one putative false-positive hit (Bordetella bronchiseptica 246 strain KU1201; contig BBVB01000043.1); however, closer inspection showed greater 247 homology of this contig to Achromobacter spp. (~95-99% identity and 97-100% coverage) 248 than Bordetella spp. (~90-91% identity and ~68-71% coverage). The closest non-249
Achromobacter hit for the Ac amplicon was in Bordetella genomosp. 7 (~89% identity and 250 100% coverage). Importantly, there were 6 SNPs in the 20bp Ac_probe sequence in these 251 taxa, which would inhibit their detection in the real-time PCR assay due to insufficient 252 sequence homology. For all 172 Achromobacter spp. genomes, there was 100% nucleotide 253 conservation at the primer-and probe-binding regions. Therefore, in silico analysis confirmed 254 excellent specificity of the Ac assay for all known members of this genus. 255
For the 127bp Ax amplicon, one putative false-positive BLAST hit was identified 256 (Achromobacter sp. RW408); however, this isolate was reclassified as A. xylosoxidans 257 according to our phylogenomic analysis (Figure 1 ), confirming an NCBI database error for this 258 strain. The closest non-A. xylosoxidans hit was in Burkholderia mesoacidophila, with BLAST 259 analysis yielding 100% coverage but only 75% sequence identity in this organism. Like the Ac 260 assay, there were 6 SNPs in the 21bp Ax_probe sequence in B. mesoacidophila, which would 261 inhibit detection of this non-target species due to substantial sequence diversity. All 55 A. 262 xylosoxidans genomes possessed 100% nucleotide conservation at the primer-and probe-263 binding sites. Therefore, this assay shows excellent in silico specificity for A. xylosoxidans. 264
Ac-Ax performance on Achromobacter isolates. Of the 119 Achromobacter isolates 265 examined with the Ac-Ax duplex real-time PCR assay, 114 were Ac-positive, and among 266 these, 48 were also Ax-positive (Table S2 ). There were no instances of Ax-positive but Ac-267 negative strains. The four type culture strains performed as expected, with all being Ac-268 positive, and only A. xylosoxidans LMG 1863 being Ax-positive; A. insuavis LMG 26845, A. 269 ruhlandii LMG 1866, and A. dolens LMG 26840 failed to amplify with the Ax assay. The five 270 isolates that did not amplify with either assay were subjected to 16S rRNA gene sequencing 271 of a ~1.3kb amplicon to determine their species identity. Of these, two (QLDACH029 and 272 QLDACH035) were identified as P. aeruginosa, and the remaining three were identified as B. 273 bronchiseptica (QLDACH105), Cupriavidus metallidurans (QLDACH120), and S. maltophilia 274 (QLDACH125). The two P. aeruginosa isolates were previously identified as Achromobacter 275 sp. according to ARDRA (39), whereas the remaining three isolates were identified as 276
Achromobacter sp. according to API 20 NE. The performance of each genotyping method and 277 concordance with the Ac-Ax duplex assay is summarised in Table 2 . 278 Ac-Ax performance on non-Achromobacter isolates. Of the 34 non-Achromobacter 279 species and 24 NTCs tested against the Ac-Ax duplex assay, none yielded detectable 280 amplification (data not shown). 281
Ac-Ax sensitivity. The lower limits of detection (LoD) and quantification (LoQ) for the Ac-Ax 282 duplex assay were determined on A. xylosoxidans LMG 1863 genomic DNA obtained from a 283 pure culture (Figure 2 ). Using a 10-fold DNA dilution series ranging from 40 ng/µL to 0.04 284 fg/µL, the LoQ for both assays was ~400 fg/µL, or ~110 genome equivalents (GEs). The LoD 285 values were more sensitive than the LoQ values, with an Ac assay LoD of ~40 fg/µL (~12 286 GEs) and an Ax LoD of ~4 fg/µL (~1 GE) ( Figure 2) . 287
Comparison of Ac-Ax and metataxonomics for Achromobacter identification from CF 288 sputa. To determine the performance of Ac-Ax on polymicrobial clinical specimens, the duplex 289 PCR was tested against 38 sputa from 21 adults with CF. Of these, five (i.e. 15%) contained 290
Achromobacter spp. at relative abundances ranging from 0.1% to 63.6% according to 291 metataxonomic sequencing (Table 3) , with the remaining 33 samples failing to identify any 292
Achromobacter 16S rRNA gene reads. Consistent with the metataxonomic findings, 4/33 293 sputa were PCR-positive according to the Ac assay, and three of these were also Ax-positive; 294 however, this species result could not be compared with the metataxonomic data due to 295 insufficient species-level resolution obtained from the 16S rRNA gene V3-V4 region. 296
The relative abundance of achromobacterial DNA between the metataxonomic and duplex 297 PCR methods was also consistent. For example, the highest proportion of achromobacterial 298 DNA was detected in SCHI0009 (difference in cycles-to-threshold [∆CT] value of 2.8 when 299 compared with the 16S rRNA gene), which possessed the highest relative abundance of 300 achromobacterial reads (63.6%) according to metataxonomics (Table 3 ). The one Ac-Ax 301 negative sample, SCHI0030 Day 6, only contained a relative abundance of 0.1% 302 achromobacterial DNA in the metataxonomic sequence data. Sputa from another patient, 303 SCHI0014, had the same low relative abundance of achromobacterial DNA but was Ac-304 positive; however, the CT value (36.3) was found to be outside the LoQ and LoD values for 305 this assay (Figure 2) , thus reflecting the stochastic nature of detection capability beyond these 306 limits. The higher sensitivity of the metataxonomic method for achromobacterial detection was 307 also expected due to the multicopy nature of the 16S rRNA gene (n=3) in Achromobacter spp. 308 compared with the single-copy nature of the Ac and Ax targets. 309
Discussion 310
Achromobacter spp. are now recognised as an important cause of severe nosocomial and 311 community-acquired infections. These Gram-negative bacteria can cause a spectrum of 312 disease including bacteraemia, cholecystitis, endocarditis, keratitis, lymphadenitis, meningitis, 313 osteomyelitis, peritonitis, pneumonia, and urinary tract infections (40, 41) . Achromobacter spp. 314 are becoming increasingly common in people with the life-shortening disease, CF, being 315 present in up to 30% of adult CF airways (13, 15, 42) . Although historically considered of low 316 pathogenic potential, there is mounting evidence that CF infections caused by Achromobacter 317 spp. are associated with adverse clinical presentations and outcomes, especially in 318 immunocompromised individuals (9, (13) (14) (15) . Therefore, their rapid identification is essential for 319 guiding appropriate therapeutic treatments and improving patient prognosis (43). 320
Several phenotypic (e.g. API 20 NE, VITEK ® MS) and genotypic (e.g. ARDRA, gene 321 sequencing, WGS, real-time PCR) methods are available to identify Achromobacter spp. 322
These methods provide varying degrees of sensitivity, specificity, cost-effectiveness, 323 turnaround time, and resolution. The gold standard method, next-generation sequencing, 324 enables highly accurate and comprehensive species identification, but is currently laborious, 325 slow (>8h to result), costly (~AUD$80 for metataxonomics or WGS), and requires specialised 326 bioinformatic tools and knowledge to analyse sequence data. VITEK ® MS is considered to 327 have good success at identifying Achromobacter spp. to the genus level; however, this method 328 currently cannot attain reliable species-level resolution, with e.g. A. xylosoxidans unable to be 329 differentiated from A. denitrificans (18), despite these species being genetically distinct ( Figure  330 1). 331
We chose the real-time PCR platform for Ac-Ax assay development due to its multiplexing 332 capability, low per-sample cost, high accuracy potential, direct detection from polymicrobial 333 specimens (e.g. sputum), excellent sensitivity, greater accessibility in lower-resourced 334 laboratories, and rapid (<1h) turnaround time (18). The upfront equipment cost of real-time 335 PCR equipment (~USD$25-40K) is also considerably less than VITEK ® MS (USD$200K) or 336 many next-generation sequencing platforms such as Illumina, and has a much smaller 337 laboratory footprint. The Ac-Ax consumables cost is comparable to VITEK ® MS at ~USD$1 338 per sample, compared with ~USD$30 for the BD Max real-time PCR platform, making the Ac-339
Ax assay a cost-effective method for achromobacterial identification. The Ac-Ax assay also 340 has the advantage of simultaneous detection of both Achromobacter sp. and A. xylosoxidans, 341
unlike most existing methods that only detect A. xylosoxidans, meaning that ~50% of 342
Achromobacter CF infections are undiagnosed with these methods (4, 10-12). 343
The Ac-Ax assay is highly accurate, with no false-positives or false-negatives identified with 344 in silico or laboratory testing. Indeed, our initial in silico BLAST analysis of Ac and Ax targets 345 resolved incorrect species assignments in two publicly available genomes: B. bronchiseptica 346 KU1201 (actually Achromobacter sp.) and Achromobacter sp. RW408 (actually A. 347 xylosoxidans), demonstrating the highly accurate nature of these targets. Laboratory testing 348 of the Ac-Ax duplex assay identified 114 of 119 previously characterised Achromobacter 349
isolates as Achromobacter spp., of which 48 (42%) were A. xylosoxidans (Table S2) achieving high-quality target identification is large-scale comparative genomic analysis to 363 identify species-and genus-level boundaries. As demonstrated by our phylogenomic analysis 364 (Figure 1) , nearly a quarter of the 158 publicly deposited Achromobacter genomes were 365 incorrectly speciated. Our study therefore demonstrates the critical importance of using large-366 scale comparative genomics for informed and accurate diagnostics development. 367
The Ac-Ax assay demonstrated good sensitivity and specificity for achromobacterial 368 identification from polymicrobial specimens, with 4/33 (12%) adult CF sputa being Ac PCR-369 positive. This rate falls within the 3 to 30% Achromobacter prevalence rates reported in CF 370 centres worldwide (13, 15, 42) . Of the four positive sputa, one patient was found to harbour a 371 non-A. xylosoxidans achromobacterial infection (Table 3 ). The Ac-Ax results were consistent 372 with metataxonomic sequencing, which identified 5/33 (15%) achromobacterial-positive sputa. 373
The one Ac-Ax PCR-negative sputum sample, collected of Day 6 of intravenous antibiotic 374 treatment in Patient SCHI0030, had a very low (~0.1%) proportion of achromobacterial rDNA 375 gene reads that exceeded the lower Ac-Ax LoD threshold (~12 and ~1 genome equivalent/s 376 for Ac and Ax, respectively). Notably, the Ac-Ax assay detected very low prevalence of A. 377 xylosoxidans in the Day 1 sputum sample from Patient SCHI0030 (CT=34.7 for both Ac and 378
Ax assays), which corresponded with a similarly low (~0.4%) proportion of achromobacterial 379 rRNA gene reads, indicating very low prevalence of this organism in this patient's airways at 380 both time points. Taken together, we show that the Ac-Ax assay provides good performance 381 on polymicrobial specimens, with the advantage of a considerable reduction in cost and 382 turnaround-time compared with metataxonomic sequencing. 383
In conclusion, we have employed a large-scale comparative genomics approach to inform the 384 design of a highly accurate duplex real-time PCR assay for the rapid, sensitive, specific, cost-385 effective, and simultaneous detection of Achromobacter sp. and A. xylosoxidans from purified 386 cultures and polymicrobial clinical specimens. Implementation of the Ac-Ax assay in the clinic 387 will enable rapid (~1h) diagnosis of these naturally drug-resistant organisms, providing the 388 opportunity for targeted antimicrobial therapy and rapid treatment shifts in response to 389 achromobacterial detection. Although beyond the scope of the current study, future work 390 whereas the Ax assay yield an LoD value of ~4 fg/µL (~1 genome equivalent). 439 
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